Stella Kyriakides

Standing for the conservative Democratic Rally, Kyriakides was elected as a deputy in the 2006 Cypriot legislative election, representing Nicosia District,[7] Since 2013, Kyriakides has served as a vice president of the Democratic Rally party, under the leadership of its president Nicos Anastasiades.[8][9]

In 2018, Kyriakides pushed for a law decriminalizing abortion in Cyprus.[9]

In addition to her parliamentary duties in Cyprus, from 2012 until 2019 Kyriakides served as the chairperson of the Cyprus delegation to the Parliamentary Assembly of the Council of Europe (PACE). From 2016 until 2018, she chaired the PACE Committee on Social Affairs, Health, and Regional Development. In October 2017, after the resignation of the Spanish member Pedro Agramunt, she ran for the presidency of the PACE, winning the voting in the third round against the Lithuanian Emanuelis Zingeris.[10][4] From 2018 until 2019, she served as the PACE representative to the Venice Commission.

Following the 2019 European elections, President Nicos Anastasiades nominated Kyriakides to become the country's next European Commissioner.[11]

In early March 2020, Kyriakides was appointed by President Ursula von der Leyen to serve on a special task force to coordinate the European Union's response to the COVID-19 pandemic.[12]

Kyriakides came under attack by the international media and the publicas her procurement of COVID-19 vaccines was said to be slow and insufficient,[13][14][15] especially in comparison to the United States and the United Kingdom.[15] AstraZeneca's CEO, Soriot, blamed the EU for being three months slower than the U.K. in finalizing its purchase agreements for the vaccine, which AstraZeneca had developed.[16] According to the German tabloid newspaper Bild-Zeitung, Germany’s Health Minister Jens Spahn had warned Chancellor Angela Merkel about Kyriakides’ slow response time.[17] However, Kyriakides rejected all criticism and defended the EU joint procurement strategy, claiming that it had "medical and social virtues".[18] She also rejected the logic of "first come, first served,", arguing "that may work at the neighborhood butcher’s but not in contracts."[19] AstraZeneca hit back, stating that the contract only included 'best efforts' to supply the EU commission, whereas the UK contract included provisions to supply the entirety of the UK from the company’s British plants first, before allowing export overseas.[20]